Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price target trimmed by HC Wainwright from $344.00 to $335.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other equities research analysts have also recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $300.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 25th. TD Cowen reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Ascendis Pharma A/S in a research note on Tuesday, October 13th. UBS Group began coverage on shares of Ascendis Pharma A/S in a report on Thursday, October 15th. They set a “buy” rating and a $269.00 price target on the stock. Finally, Barclays dropped their price target on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Nineteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $313.52.
Check Out Our Latest Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Stock Performance
NASDAQ ASND opened at $275.39 on Friday. The stock has a 50-day simple moving average of $242.67 and a two-hundred day simple moving average of $239.83. The firm has a market capitalization of $17.18 billion, a P/E ratio of 18.00 and a beta of 0.40. Ascendis Pharma A/S has a fifty-two week low of $188.08 and a fifty-two week high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 73.26% and a return on equity of 44.80%. The company had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. On average, equities analysts forecast that Ascendis Pharma A/S will post 3.43 earnings per share for the current year.
Insider Transactions at Ascendis Pharma A/S
In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 40.00% of the company’s stock.
Institutional Trading of Ascendis Pharma A/S
Institutional investors and hedge funds have recently made changes to their positions in the business. Empowered Funds LLC lifted its position in shares of Ascendis Pharma A/S by 0.5% during the 3rd quarter. Empowered Funds LLC now owns 188,229 shares of the biotechnology company’s stock valued at $42,884,000 after buying an additional 958 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in Ascendis Pharma A/S by 2.6% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 34,235 shares of the biotechnology company’s stock valued at $7,800,000 after acquiring an additional 852 shares during the period. First Trust Advisors LP grew its stake in Ascendis Pharma A/S by 435.8% in the 3rd quarter. First Trust Advisors LP now owns 86,940 shares of the biotechnology company’s stock valued at $19,807,000 after acquiring an additional 70,714 shares during the period. Allianz SE increased its holdings in Ascendis Pharma A/S by 219.4% in the 3rd quarter. Allianz SE now owns 16,215 shares of the biotechnology company’s stock worth $3,694,000 after acquiring an additional 11,138 shares in the last quarter. Finally, Advisors Asset Management Inc. purchased a new stake in Ascendis Pharma A/S in the 3rd quarter worth $6,075,000.
More Ascendis Pharma A/S News
These are some of the ASND news items that stood out recently:
- Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
- Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.
- Negative Sentiment: Employee warrants may cause modest dilution. Ascendis granted 28,030 employee warrants, creating a potential increase in shares outstanding if exercised. Read More.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
